Research

Cellular

GLP-1RA users had a lower risk of all-cause mortality (HR, 0.70; 95% CI, 0.63-0.78) compared to other antidiabetic drug users.

Practitioners may consider GLP-1RAs as a treatment option for reducing all-cause mortality in this population.

StrongSupportsmedium confidence
GLP-1RA users had a lower risk of all-cause mortality (HR, 0.70; 95% CI, 0.63-0.78).
Huan-Tang Lin et al. · JAMA Network Open · 2025

Why this rating

Based on the large cohort study design.

Source

Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity

Huan-Tang Lin et al. · JAMA Network Open · 2025

DOI 10.1001/jamanetworkopen.2025.21016

cohort · n=60860Cited 21×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →